1.70
-0.11(-6.08%)
Currency In USD
| Previous Close | 1.81 |
| Open | 1.81 |
| Day High | 1.84 |
| Day Low | 1.68 |
| 52-Week High | 65.2 |
| 52-Week Low | 1.52 |
| Volume | 48,646 |
| Average Volume | 73,396 |
| Market Cap | 4.19M |
| PE | -0.1 |
| EPS | -17.23 |
| Moving Average 50 Days | 2.04 |
| Moving Average 200 Days | 7.6 |
| Change | -0.11 |
If you invested $1000 in Autonomix Medical, Inc. Common Stock (AMIX) since IPO date, it would be worth $16.77 as of May 09, 2025 at a share price of $1.7. Whereas If you bought $1000 worth of Autonomix Medical, Inc. Common Stock (AMIX) shares 6 months ago, it would be worth $159.62 as of May 09, 2025 at a share price of $1.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain
GlobeNewswire Inc.
May 05, 2025 12:30 PM GMT
Video testimonial demonstrates pain reduction after transvascular nerve ablation, suggesting potential for improving quality of life in late-stage cancer care Patient testimonial now available here THE WOODLANDS, TX, May 05, 2025 (GLOBE NEWSWIRE) -
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain
GlobeNewswire Inc.
May 01, 2025 1:25 PM GMT
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase (“POC 1”) where clinically meaningful pain reduction was demonstrated Outlines Company’s plans to initiate market expansion study (“POC 2”) into
Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain
GlobeNewswire Inc.
Apr 30, 2025 12:15 PM GMT
Figure: 1 Pancreatic Cancer Pain PoC 1 STUDY Initial trial phase (“PoC 1”) achieved key learnings and met all study objectives Clinically meaningful pain reduction with 100% of responders achieving zero opioid use at 7 days post-procedure and 73%